Skip to main content

Table 1 Sociodemographic and clinical data

From: Gender differences in quality of life in adults with long-standing type 1 diabetes mellitus

 

Total

Male

Female

Number of patients (n, %)

312, 100%

161, 51.6%

151, 48.4%

Age (years)

38.2 ± 12.7

38.7 ± 12.7

37.7 ± 12.6

Education (years)

13.4 ± 4.7

13.2 ± 4.8

13.6 ± 4.7

Marital status:

 Single

103 (33%)

54 (33.5%)

49 (32.4%)

 Married

151 (48.4%)

75 (46.5%)

76 (50.3%)

 Divorced

23 (7.3%)

15 (9.4%)

8 (5.4%)

 Widowed

6 (1.9%)

2 (1.3%)

4 (2.6%)

 In a relationship

29 (9.3%)

15 (9.3%)

14 (9.3%)

Age at diagnosis (years)

17.7 ± 10.7

17.6 ± 11.1

17.7 ± 10.3

Duration of diabetes (years)

20.4 ± 12

20.7 ± 12.4

19.9 ± 11.6

HbA1c (%)

7.5 ± 1.1

7.5 ± 1.2

7.5 ± 1

Glycemic Instabilitya

9.2 ± 8.3

9.4 ± 9.3

8.4 ± 7.1

 Hypertension

77 (24.6%)

47 (29.2%)

30 (19.9%)*

 Unawareness hypoglycemic

95 (30.4%)

54 (33.5%)

41 (27.1%)

Severe hypoglycemia (last year):

 0

244 (78.2%)

127 (78.9%)

117 (77.5%)

 1

35 (11.2%)

18 (11.2%)

17 (11.25%)

 > 1

33 (10.6%)

16 (9.9%)

17 (11.25%)

Intensive insulin regimen:

312 (100%)

161 (100%)

151 (100%)

 Bolus Basal

287 (92%)

152 (94.4%)

135 (89.4%)

 CSII

23 (7.4%)

9 (5.6%)

14 (9.3%)

 Insulin regimen < 2 shots a day

2 (0.6%)

0 (0.0%)

2 (1.3%)

Microvascular complications:

192 (61.5%)

108 (67%)

84 (55.6%)

 Retinopathy

107 (34.3%)

61 (37.9%)

46 (30.5%)

 Nephropathy

62 (19.9%)

34 (21.1%)

28 (18.5%)

 Neuropathy

23 (7.4%)

13 (8.1%)

10 (6.6%)

Macrovascular complications

14 (4.5%)

11 (6.8%)

3 (1.9%)*

Fear of hypoglycemia

139 (44.6%)

70 (43.5%)

69 (45.7%)

Depression (MINI)

72 (23.1%)

24 (14.9%)

48 (31.7%)*

Anxiety (MINI)

56 (17.9%)

21 (13%)

35 (23.2%)*

  1. Data are expressed as Mean ± SD or n (%)
  2. Prevalence of Fear of Hypoglycemia is calculated according to FH-15 questionnaire
  3. CSII, Continuous subcutaneous insulin infusion; MINI, Planned psychological interview
  4. aGlycemic instability is defined as number of episodes of severe hypoglycaemia, mild hypoglycaemia (≤ 70 mg/dl) and hyperglycemic excursions (≥ 250 mg/dl) in 15 days prior to evaluation
  5. *p < 0.05